Videos

“We really felt that this was an important question to ask because we know that OAB therapy adherence is associated with improvements in urinary symptoms, quality of life, and decreased OAB-related health care costs,” says Ekene Enemchukwu, MD, MPH.

The panel explains the science behind PSMA PET scans and reviews the different positron-emitters used in the scans.

A background on the available options and recent advances in prostate cancer imaging.

“We look forward to the optimization of these drugs,” says Scott T. Tagawa, MD, MS, FACP.

"The seminal innovation was the idea that you could create a focused shock wave that could be delivered into the body in a non-invasive way that had sufficient energy to break up a stone but not damage other structures," says James E. Lingeman, MD.

Drs MacDiarmid and Rogers discuss barriers to OAB treatments and therapies on the horizon.

“Whether it is E-cigarettes or other products, the goal should be complete cessation,” says Omar El Shahawy, MD, MPH, PhD.

“I think [this study] really addresses an unmet need for practicing urologists across the world,” says Fred Saad, MD, FRCS.

“We certainly need to move away from a model of care that is follow up driven by tumor markers or imaging alone,” says Netty Kinsella, RN, MSc, PhD.

“There are many studies now that have shown that these doublets and triplets seem to be better than just ADT alone,” says William K. Oh, MD.

“One thing from our study that you can take home [is] no matter what the surgery is, small changes right after surgery can actually tell you more than we usually give them credit for,” says Sevag Demirjian, MD.

“I think we need to change the mindset that chemotherapy is a bad thing. It is a very good thing when given appropriately and when patients are more likely to get long-term benefit,” says Fred Saad, MD, FRCS.

“The take home message would be that in patients with prior history of kidney stone episodes…receiving 24-hour urine testing prior to starting pharmacologic preventive therapy is associated with a lower probability of a subsequent stone-related event,” says Ryan Hsi, MD, FACS.

“I think this is an extremely exciting space,” says Jai Seth, MD, BSc, MSc, FRCS.

“[The prediction model] worked way better than we expected that it would work,” says Sevag Demirjian, MD.

“Botox has been a wonderful drug for many, many years,” says Min Dong, MD.

“There are many trials that clinicians should be aware of,” says Daniel P. Petrylak, MD.

“The take-home message is that it's not a question of if you're going to start doing a hereditary cancer risk assessment, it's when,” says Neal D. Shore, MD, FACS.

“One of the reasons I so enjoy this conference is the multidisciplinary nature,” says Peter A. Humphrey, MD, PhD.

“It’s not only about prescribing medications or advising how to use it. It’s about support. It’s about checking how things are going. It’s about motivation when things are primarily not working. It’s about knowledge that things tend to improve with time, and certain functions can just recover independently,” says Marta Skrodzka, MD, PhD.

"It is clearly the standard and it's the treatment of choice. When you have that, and it's very good, it's evidenced by the fact that none of the agents are compared against BCG because it sets such a high standard of effectiveness," says Sam S. Chang, MD, MBA.

OAB experts share their experience with reimplantation of a tibial nerve stimulation device (eCoin).

Drs Rogers and MacDiarmid discuss data from feasibility and pivotal studies with eCoin, a tibial nerve stimulation device, and how it compares to other third-line treatments.

“There are, indeed, numerous paths that we are trying to tackle from different angles,” says Gennady Bratslavsky, MD.

“We actually found that treatment with percutaneous tibial nerve stimulation was…a safe and very effective way of improving sexual function,” says Varun R. Talanki, MD.

“I think one of the problems is that we do run out of treatments in many of these patients at some point,” says William K. Oh, MD.

“I think this really gave us an advantage to offer better care,” says Shiva J. Maralani, MD.

“I think that it's very clear that this test is independently prognostic,” says Daniel E. Spratt, MD.

“As [nurse specialists], we are uniquely placed in terms of supporting these men through their prostate cancer treatments, and then, obviously, through to their recovery afterwards,” says Netty Kinsella, RN, MSc, PhD.

“The fascinating thing is that we have so many new treatments that are now available to us,” says Leonard G. Gomella, MD, FACS.